{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:37:18Z","timestamp":1767155838377,"version":"3.48.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01448-w","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:34:41Z","timestamp":1767155681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real world outcomes with the use of Inotuzumab Ozogamicin in relapsed\/refractory B cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Archita","family":"Ravindranath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-2424","authenticated-orcid":false,"given":"Uday","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4045-3496","authenticated-orcid":false,"given":"Sushil","family":"Selvarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Lionel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha M.","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Korula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-110X","authenticated-orcid":false,"given":"Phaneendra","family":"Datari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpesh Bipinbhai","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NA","family":"Fouzia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9443-439X","authenticated-orcid":false,"given":"Poonkuzhali","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-9501","authenticated-orcid":false,"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-2353","authenticated-orcid":false,"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"1448_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524\u201333. https:\/\/doi.org\/10.3324\/haematol.2016.144311.","journal-title":"Haematologica"},{"key":"1448_CR2","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387. https:\/\/doi.org\/10.1002\/cncr.32116.","journal-title":"Cancer"},{"key":"1448_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.clml.2020.03.004","volume":"20","author":"T Badar","year":"2020","unstructured":"Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, et al. Real-world outcomes of adult b-cell acute lymphocytic leukemia patients treated with Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. 2020;20:556\u2013.e2. https:\/\/doi.org\/10.1016\/j.clml.2020.03.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1448_CR4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2217\/fon-2022-1314","volume":"19","author":"T Moribe","year":"2023","unstructured":"Moribe T, Xu L, Tajima K, Yonemoto N. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan. Future Oncol. 2023;19:1343\u201356. https:\/\/doi.org\/10.2217\/fon-2022-1314.","journal-title":"Future Oncol"},{"key":"1448_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/10428194.2019.1672057","volume":"61","author":"CSY Lecat","year":"2020","unstructured":"Lecat CSY, Besley C, Hough RE, Khwaja A, Furness C, Marks DI, et al. Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data. Leuk Lymphoma. 2020;61:491\u20133. https:\/\/doi.org\/10.1080\/10428194.2019.1672057.","journal-title":"Leuk Lymphoma"},{"key":"1448_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1171568","volume":"13","author":"V Mathews","year":"2023","unstructured":"Mathews V, Korula A, Chakrapani A, Bhurani D, Bhattacharyya J, Sengar M, et al. Management of B-cell lineage acute lymphoblastic leukemia: expert opinion from an Indian panel via Delphi consensus method. Front Oncol. 2023;13:1171568. https:\/\/doi.org\/10.3389\/fonc.2023.1171568.","journal-title":"Front Oncol"},{"key":"1448_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1601782","volume":"15","author":"N Agrawal","year":"2025","unstructured":"Agrawal N, Boyella PK, Bhargava R, Nair CK, Nag A. A retrospective analysis of inotuzumab ozogamicin usage in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Front Oncol. 2025;15:1601782. https:\/\/doi.org\/10.3389\/fonc.2025.1601782.","journal-title":"Front Oncol"},{"key":"1448_CR8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1891\u2013902. https:\/\/doi.org\/10.1182\/blood.2023020794.","journal-title":"Blood"},{"key":"1448_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2023;58:749\u201354. https:\/\/doi.org\/10.1038\/s41409-023-01992-8.","journal-title":"Bone Marrow Transplant"},{"key":"1448_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11523-025-01129-5","volume":"20","author":"M de Lima","year":"2025","unstructured":"de Lima M, Marks DI. CIBMTR registry data on inotuzumab ozogamicin treatment in patients with all who proceeded to hematopoietic stem cell transplant-A podcast. Target Oncol. 2025;20:371\u20134. https:\/\/doi.org\/10.1007\/s11523-025-01129-5.","journal-title":"Target Oncol"},{"key":"1448_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01098-4","volume":"14","author":"J Senapati","year":"2024","unstructured":"Senapati J, Jabbour E, Short NJ, Jain N, Haddad F, Bathala T, et al. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024;14:129. https:\/\/doi.org\/10.1038\/s41408-024-01098-4.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01448-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:34:48Z","timestamp":1767155688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01448-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01448-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}